FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3069881646> ?p ?o ?g. }

• W3069881646 abstract "Abstract Background Metaplastic breast carcinoma (MBC) is a rare histological type of breast cancer, which commonly shows resistance to standard therapies and is associated with poor prognosis. The immune microenvironment in MBC and its significance has not been well established due to its low incurrence rate and complex components. We aimed to investigate the diversity of immune parameters including subsets of TILs and PDL1/PD1 expression in MBC, as well as its correlation with prognosis. Methods A total of 60 patients diagnosed with MBC from January 2006 to December 2017 were included in our study. The percentage (%) and quantification (per mm 2 ) of TILs and presence of tertiary lymphoid structures (TLS) were evaluated by hematoxylin and eosin staining (HE). The quantification of CD4+, CD8+ TILs (per mm 2 ), and PD-1/PDL1 expression were evaluated through immunohistochemistry and analyzed in relation to clinicopathological characteristics. A ≥ 1% membranous or cytoplasmatic expression of PD1 and PDL1 was considered a positive expression. Results We found squamous cell carcinoma MBC (33/60, 55%) exhibiting most TILs of all the MBC subtypes ( p = 0.043). Thirty-three of 60 (50%) of the patients had coexisting invasive ductal carcinoma of no special type (IDC-NST), and the average percentage of TILs in MBC components was lower compared with NST components ( p < 0.001). Thirty (50%) patients exhibited positive (≥ 1%) PDL1 expression in their tumor cells, while 36 (60%) had positive (≥ 1%) PDL1 expression in their TILs. Twenty-seven (45%) of all the patients had positive (≥ 1%) PD1 expression in their tumor cells and 33 (55%) had PD1-positive (≥ 1%) stromal TILs. More CD8+ TILs were associated with positive PDL1 expression of tumor cells as well as positive PD1 expression in stromal cells. Greater number of stromal TILS (> 300/mm 2 , 20%), CD4+ TILs (> 250/mm 2 ), and CD8+ TILs (> 70/mm 2 ) in MBC were found associated with longer disease-free survival. Positive expression of PDL1 in tumor cells (≥ 1%) and PD1 in stromal cells (≥ 1%) were also associated with longer survival. Conclusions The immune characteristics differ in various subtypes as well as components of MBC. Immune parameters are key predictive factors of MBC and provide the clinical significance of applying immune checkpoint therapies in patients with MBC." @default.
• W3069881646 created "2020-08-24" @default.
• W3069881646 creator A5009884211 @default.
• W3069881646 creator A5013881064 @default.
• W3069881646 creator A5015287299 @default.
• W3069881646 creator A5039568808 @default.
• W3069881646 creator A5040265500 @default.
• W3069881646 creator A5045069560 @default.
• W3069881646 creator A5047119343 @default.
• W3069881646 creator A5070346853 @default.
• W3069881646 creator A5073309453 @default.
• W3069881646 date "2020-08-18" @default.
• W3069881646 modified "2023-10-11" @default.
• W3069881646 title "Immune parameters associated with survival in metaplastic breast cancer" @default.
• W3069881646 cites W1729209718 @default.
• W3069881646 cites W1969181991 @default.
• W3069881646 cites W2002673891 @default.
• W3069881646 cites W2050877429 @default.
• W3069881646 cites W2057186227 @default.
• W3069881646 cites W2067214617 @default.
• W3069881646 cites W2081447339 @default.
• W3069881646 cites W2098683355 @default.
• W3069881646 cites W2100413206 @default.
• W3069881646 cites W2111225997 @default.
• W3069881646 cites W2112434826 @default.
• W3069881646 cites W2112790287 @default.
• W3069881646 cites W2120338564 @default.
• W3069881646 cites W2120404172 @default.
• W3069881646 cites W2134878729 @default.
• W3069881646 cites W2139398669 @default.
• W3069881646 cites W2204673465 @default.
• W3069881646 cites W2254576822 @default.
• W3069881646 cites W2260996817 @default.
• W3069881646 cites W2277555391 @default.
• W3069881646 cites W2294216513 @default.
• W3069881646 cites W2345415641 @default.
• W3069881646 cites W2409195327 @default.
• W3069881646 cites W2530700542 @default.
• W3069881646 cites W2559561655 @default.
• W3069881646 cites W2578980111 @default.
• W3069881646 cites W2607223351 @default.
• W3069881646 cites W2609874944 @default.
• W3069881646 cites W2610371878 @default.
• W3069881646 cites W2626585215 @default.
• W3069881646 cites W2744685612 @default.
• W3069881646 cites W2761177724 @default.
• W3069881646 cites W2761720249 @default.
• W3069881646 cites W2794560540 @default.
• W3069881646 cites W2888914413 @default.
• W3069881646 cites W2889746019 @default.
• W3069881646 cites W2897422388 @default.
• W3069881646 cites W2902530914 @default.
• W3069881646 cites W2944487499 @default.
• W3069881646 cites W2944905511 @default.
• W3069881646 cites W2945915077 @default.
• W3069881646 cites W2950563001 @default.
• W3069881646 cites W2950802753 @default.
• W3069881646 cites W2979724228 @default.
• W3069881646 cites W2980933209 @default.
• W3069881646 cites W2990398119 @default.
• W3069881646 doi "https://doi.org/10.1186/s13058-020-01330-6" @default.
• W3069881646 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7437173" @default.
• W3069881646 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32811533" @default.
• W3069881646 hasPublicationYear "2020" @default.
• W3069881646 type Work @default.
• W3069881646 sameAs 3069881646 @default.
• W3069881646 citedByCount "20" @default.
• W3069881646 countsByYear W30698816462020 @default.
• W3069881646 countsByYear W30698816462021 @default.
• W3069881646 countsByYear W30698816462022 @default.
• W3069881646 countsByYear W30698816462023 @default.
• W3069881646 crossrefType "journal-article" @default.
• W3069881646 hasAuthorship W3069881646A5009884211 @default.
• W3069881646 hasAuthorship W3069881646A5013881064 @default.
• W3069881646 hasAuthorship W3069881646A5015287299 @default.
• W3069881646 hasAuthorship W3069881646A5039568808 @default.
• W3069881646 hasAuthorship W3069881646A5040265500 @default.
• W3069881646 hasAuthorship W3069881646A5045069560 @default.
• W3069881646 hasAuthorship W3069881646A5047119343 @default.
• W3069881646 hasAuthorship W3069881646A5070346853 @default.
• W3069881646 hasAuthorship W3069881646A5073309453 @default.
• W3069881646 hasBestOaLocation W30698816461 @default.
• W3069881646 hasConcept C121608353 @default.
• W3069881646 hasConcept C125473707 @default.
• W3069881646 hasConcept C126322002 @default.
• W3069881646 hasConcept C142724271 @default.
• W3069881646 hasConcept C143998085 @default.
• W3069881646 hasConcept C167672396 @default.
• W3069881646 hasConcept C203014093 @default.
• W3069881646 hasConcept C204232928 @default.
• W3069881646 hasConcept C2776107976 @default.
• W3069881646 hasConcept C2777546739 @default.
• W3069881646 hasConcept C2778326572 @default.
• W3069881646 hasConcept C2780140570 @default.
• W3069881646 hasConcept C3018521938 @default.
• W3069881646 hasConcept C530470458 @default.
• W3069881646 hasConcept C71924100 @default.
• W3069881646 hasConcept C8891405 @default.
• W3069881646 hasConceptScore W3069881646C121608353 @default.
• W3069881646 hasConceptScore W3069881646C125473707 @default.

• next